Physician profile
Roberto Belli
NPI 1770879264
$2,420.56
in general payments reported to CMS, 2019-2025
23 companies · $358 in 2025
The $358 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $256 · 2022: $337 · 2023: $446 · 2024: $1,023 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,544 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,544.11 |
| Education | $283.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $414.26 | 2023-2025 | Tremfya |
| Amgen INC. | $342.24 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $319.76 | 2022-2025 | Opzelura |
| Abbvie INC. | $169.30 | 2021-2024 | Skyrizi |
| Galderma Laboratories, L.P. | $168.72 | 2022-2024 | |
| Almirall LLC | $149.41 | 2021 | |
| Lilly USA, LLC | $134.35 | 2022-2024 | Taltz, Olumiant, Zepbound |
| Regeneron Healthcare Solutions, INC. | $126.11 | 2023-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $115.51 | 2023-2024 | Odomzo, Blu-U, Winlevi |
| Novartis Pharmaceuticals Corporation | $88.13 | 2023-2024 | |
| Ucb, INC. | $59.30 | 2023-2024 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $57.94 | 2022-2023 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $45.57 | 2024 | Jublia, Cabtreo |
| Arcutis Biotherapeutics, INC. | $30.15 | 2023-2024 | Zoryve |
| Organon LLC | $29.86 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $25.80 | 2025 | Vyjuvek |
| Leo Pharma INC. | $24.59 | 2025 | Anzupgo |
| Janssen Scientific Affairs, LLC | $23.33 | 2024 | Tremfya |
| Journey Medical Corporation | $21.76 | 2025 | |
| Dermavant Sciences, INC. | $20.45 | 2024 | Vtama |
| Genzyme Corporation | $19.86 | 2024 | |
| Helsinn Therapeutics (U.S.), INC. | $18.89 | 2023 | Valchlor |
| Pfizer INC. | $15.27 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Belli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.